Teen Marijuana Abuse Treatment: What Works

The treatments with real evidence behind them are behavioural and family-based: motivational enhancement therapy combined with CBT, multidimensional family therapy, the adolescent community reinforcement approach, and structured family therapies. No medication is approved for cannabis use disorder at any age. Outcomes are meaningful but modest — across trials, somewhere between a quarter and a half of adolescents reach abstinence or minimal use, depending on the programme and what it was compared against.

If you are a parent reading this after finding something in a bedroom, that is the short version. Here is what each approach actually involves, what the numbers mean, and how to work out what to ask for.

Why teenagers are treated differently

Adult cannabis treatment is largely individual. Adolescent treatment is not, and the reason is not sentimentality about families.

Adolescence is an active period of brain development, and NIDA is direct that cannabis use may influence the brain in ways that could lead to long-term harmful effects — naming working memory, processing speed and verbal memory, reduced academic functioning, poorer educational and employment outcomes in young adulthood, and increased likelihood of developing psychosis. The same page notes that starting younger raises the chance of developing a cannabis use disorder later, and puts the disorder's overall prevalence among cannabis users in the range of 22% to 30%.

That combination — a developing brain, a household, a school, and a peer group all in play — is why the interventions that work best for teenagers reach past the teenager. It is also why a programme that will not involve you is worth asking questions about.

The approaches with evidence behind them

These are the named treatments a good provider will recognise. The figures come from a review of adolescent cannabis use disorder treatment, and they are outcome rates measured across trial populations, not predictions for any one adolescent.

MET/CBT — motivational enhancement plus cognitive behavioural therapy. The most-studied option and the leanest. The standard MET/CBT5 protocol is two individual motivational sessions followed by three group CBT sessions, teaching cognitive restructuring, refusal skills and mood regulation. In trials, 23% to 27% of adolescents reached recovery — no past-month substance use — at 12 months, and extended versions performed similarly or slightly better. In the large Cannabis Youth Treatment study, MET/CBT was the most cost-effective option tested.

MDFT — multidimensional family therapy. Works across four domains at once: the adolescent's coping and emotion regulation, parenting skills, family interaction, and the world outside the family. Studies found 18% to 64% achieving minimal use or abstinence, against 14% to 44% in comparison groups, with effect sizes ranging from small to large. Those are wide ranges because the trials differed; the direction is consistent.

A-CRA — adolescent community reinforcement approach. Builds up activities and social reinforcement that compete with using. One trial showed 34% reaching recovery at 12 months, and when A-CRA was paired with assertive continuing care, 52% were cannabis-abstinent at three months against 31% in usual care.

Structured family therapies. Brief strategic family therapy produced 41% abstinence at the end of treatment against 13% in controls in one trial, though results were mixed across others. Multisystemic therapy showed longer-term abstinence of 55% against 28% in usual services at four-year follow-up.

Contingency management. Concrete rewards for clean tests and attendance. It reliably improves abstinence while it is running, particularly added to another treatment — but the review is blunt that improvements observed during treatment often did not persist at follow-up. Useful as a component, not as the whole plan.

The pattern across all of it: several approaches work, none dominates, and the ones involving the family hold up well. A meta-analysis of outpatient adolescent substance use treatment found family-based therapies most effective overall.

What about medication

There is none to ask for, and being clear about this saves months.

NIDA states there are currently no FDA-approved medications for the treatment of cannabis use disorder or for medically assisted withdrawal. That holds for adolescents too.

Two agents come up. N-acetylcysteine showed the most promise: 40.9% of young people receiving NAC had negative urine tests during treatment against 27.7% on placebo, though the benefit diminished once treatment stopped. Topiramate ran into tolerability problems, with only 48% completing treatment against 77% on placebo. Neither is an approved treatment, and anyone presenting a medication as the answer here is ahead of the evidence.

Reading the numbers honestly

It is worth sitting with what those percentages mean, because the gap between them and the language treatment programmes use in their marketing is where a lot of parental disappointment gets manufactured.

A 12-month recovery rate in the twenties is a real effect. It is also a majority who did not reach sustained abstinence in that window. Adult treatment looks similar — the Cochrane review of psychosocial interventions for cannabis use disorder found modest reductions in use and rated the evidence for abstinence as low quality.

Three things follow from that.

Treatment reduces use even when it does not end it, and reduced use in a fifteen-year-old is a genuinely different trajectory from continued heavy use. Second, a return to using is a common part of the course rather than proof the treatment failed — a programme that treats one relapse as discharge is one to ask hard questions about. Third, the continuing-care findings suggest that what happens after the programme matters as much as the programme.

What to actually do

Get an assessment before choosing a programme. Cannabis use in a teenager frequently sits alongside something else — anxiety, depression, ADHD, trauma, other substances. Which of those is present changes what treatment fits. Evidence suggests younger adolescents and those with co-occurring psychiatric problems tend to do better with family therapy, while older adolescents without those complications do comparatively well with individual CBT.

Ask providers three specific questions. Which named, manualised approach do you use? How is the family involved? What happens in the six months after the programme ends? Vague answers to any of the three are informative.

Do not lead with a drug test. Testing tells you about the last few weeks and nothing about why. It is a monitoring tool that some programmes use inside a plan, not a substitute for an assessment, and deploying it as an opening move usually costs you the conversation.

Expect withdrawal if use has been heavy and daily. Irritability, sleep trouble, appetite loss and low mood, typically starting a day or two after stopping and easing over a couple of weeks. Our rundown of withdrawal symptoms covers the shape of it, so you can recognise it as the process rather than a crisis. If the question of stopping abruptly versus cutting down comes up, the trade-offs between the two are the same for teenagers, with the strong caveat that this decision belongs with the clinician here rather than at the kitchen table.

Work out what you are dealing with before you escalate. The eleven-question dependence check is written for adults assessing themselves, but the criteria it walks through are the ones a clinician will use.

Get your own support in place. How you respond day to day changes outcomes in family-based treatment, which is exactly why those programmes spend sessions on parenting practice. Our guide to supporting someone who is quitting covers what helps and the well-meant responses that backfire, and much of it transfers. So does the general principle in how to raise the subject at all — say it plainly, ask for one specific thing.

One note on this site's own tool: Dehaze is a self-directed tracking app for adults who are stopping. It is not treatment, it is not designed for adolescents, and it is not a substitute for any of the programmes above.

When this needs more than an appointment

Move faster than a referral queue if any of these are present:

• psychosis, hallucinations or severe paranoia
• thoughts of self-harm or suicide
• other substances, particularly alcohol, benzodiazepines or opioids
• persistent vomiting with compulsive hot bathing, which suggests cannabinoid hyperemesis
• a sharp deterioration in mood, weight or functioning
• pregnancy

In the US, SAMHSA's National Helpline is free, confidential and open 24/7 at 1-800-662-4357. If there is immediate danger, call your local emergency number. Our articles are written to a clinical standard set by our medical reviewer, and this is precisely the situation where a page is a starting point and an assessment is the actual answer.

The short version

Teen marijuana abuse treatment that works is behavioural and usually involves the family: MET/CBT, MDFT, A-CRA and structured family therapies all have randomised trials behind them, with contingency management useful as an added component while it runs. No medication is approved.

Outcome rates run from roughly a quarter to around half reaching abstinence or minimal use depending on the programme and the comparison. That is a real effect, and it is not the same as the problem being resolved. Get an assessment before picking a programme, ask how the family is involved and what continuing care looks like, and treat a relapse as part of the course rather than the end of it.

Sources

• Treatment of Adolescent Cannabis Use Disorders — MET/CBT, MDFT, A-CRA, family therapies, contingency management, and the N-acetylcysteine and topiramate trial results
• National Institute on Drug Abuse — Cannabis (Marijuana) — effects on the developing brain, cannabis use disorder rates, and the absence of approved medications
• Psychosocial interventions for cannabis use disorder — Cochrane review — modest reductions in use and the quality of evidence for abstinence
• SAMHSA National Helpline — free, confidential support, 24/7, 1-800-662-4357